Total Payments
$16,508
2024 Payments
$4,378
Companies
68
Transactions
737
Medicare Patients
672
Medicare Billing
$66,425
Payment Breakdown by Category
Food & Beverage$16,304 (98.8%)
Education$204.00 (1.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $16,304 | 728 | 98.8% |
| Education | $204.00 | 9 | 1.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,366 | 64 | $0 (2024) |
| Incyte Corporation | $1,276 | 46 | $0 (2024) |
| Janssen Biotech, Inc. | $1,064 | 56 | $0 (2024) |
| Merck Sharp & Dohme LLC | $1,017 | 44 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $985.76 | 51 | $0 (2024) |
| Celgene Corporation | $835.79 | 32 | $0 (2024) |
| PFIZER INC. | $815.98 | 49 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $651.00 | 39 | $0 (2024) |
| Eisai Inc. | $632.30 | 35 | $0 (2024) |
| Exelixis Inc. | $600.45 | 15 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,378 | 192 | Celgene Corporation ($381.69) |
| 2023 | $4,191 | 182 | Incyte Corporation ($436.99) |
| 2022 | $3,783 | 186 | Novartis Pharmaceuticals Corporation ($364.89) |
| 2021 | $1,410 | 63 | Janssen Biotech, Inc. ($227.14) |
| 2020 | $2,064 | 102 | Foundation Medicine, Inc. ($143.70) |
| 2019 | $311.94 | 6 | Incyte Corporation ($108.66) |
| 2018 | $152.85 | 4 | Novartis Pharmaceuticals Corporation ($94.76) |
| 2017 | $216.89 | 2 | E.R. Squibb & Sons, L.L.C. ($122.11) |
All Payment Transactions
737 individual payment records from CMS Open Payments — Page 1 of 30
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $16.74 | General |
| Category: Oncology | ||||||
| 12/19/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI, TALVEY | Food and Beverage | In-kind items and services | $31.93 | General |
| Category: Oncology | ||||||
| 12/17/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $24.77 | General |
| Category: Hematology | ||||||
| 12/14/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $35.56 | General |
| Category: Oncology | ||||||
| 12/12/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $25.09 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/11/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $25.06 | General |
| Category: Hematology/Oncology | ||||||
| 12/10/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $26.75 | General |
| Category: Oncology | ||||||
| 12/09/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $26.88 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2024 | TerSera Therapeutics LLC | Xermelo (Drug) | Food and Beverage | In-kind items and services | $36.23 | General |
| Category: Oncology | ||||||
| 12/05/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $16.25 | General |
| Category: Oncology | ||||||
| 12/02/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $27.64 | General |
| Category: Oncology | ||||||
| 12/02/2024 | Astellas Pharma US Inc | Vyloy (Drug) | Food and Beverage | In-kind items and services | $19.02 | General |
| Category: Oncology | ||||||
| 11/25/2024 | Lilly USA, LLC | VERZENIO (Drug), RETEVMO, JAYPIRCA | Food and Beverage | In-kind items and services | $21.82 | General |
| Category: Oncology | ||||||
| 11/22/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $18.91 | General |
| Category: Hematology/Oncology | ||||||
| 11/15/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | GILOTRIF (Drug) | Food and Beverage | In-kind items and services | $32.48 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $34.99 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 11/13/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $26.99 | General |
| Category: ONCOLOGY | ||||||
| 11/12/2024 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug) | Food and Beverage | In-kind items and services | $21.55 | General |
| Category: Oncology | ||||||
| 11/10/2024 | Stemline Therapeutics Inc. | ELZONRIS (Drug) | Food and Beverage | In-kind items and services | $17.40 | General |
| Category: Oncology | ||||||
| 11/08/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $25.61 | General |
| Category: Oncology | ||||||
| 11/06/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $19.49 | General |
| Category: ONCOLOGY | ||||||
| 11/05/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Food and Beverage | In-kind items and services | $30.76 | General |
| Category: Genetically Defined Disease | ||||||
| 11/05/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $26.26 | General |
| 10/30/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $18.46 | General |
| Category: ONCOLOGY | ||||||
| 10/30/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $2.54 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 32 | 56 | $10,926 | $4,147 |
| 2022 | 1 | 25 | 58 | $11,664 | $4,327 |
| 2021 | 9 | 290 | 351 | $86,428 | $26,989 |
| 2020 | 8 | 325 | 563 | $77,939 | $30,962 |
Total Patients
672
Total Services
1,028
Medicare Billing
$66,425
Procedure Codes
23
All Medicare Procedures & Services
23 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 17 | 30 | $5,856 | $2,254 | 38.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 15 | 26 | $5,070 | $1,893 | 37.3% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 25 | 58 | $11,664 | $4,327 | 37.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 75 | 101 | $23,922 | $7,369 | 30.8% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 63 | 63 | $18,396 | $5,463 | 29.7% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 32 | 32 | $13,368 | $3,998 | 29.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 27 | 30 | $9,929 | $3,148 | 31.7% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2021 | 13 | 17 | $6,076 | $2,191 | 36.1% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 33 | 41 | $5,990 | $1,981 | 33.1% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | Office | 2021 | 11 | 24 | $4,334 | $1,610 | 37.1% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Office | 2021 | 24 | 25 | $3,019 | $704.72 | 23.3% |
| 96367 | Infusion into a vein for therapy prevention or diagnosis additional sequential infusion up to 1 hour | Office | 2021 | 12 | 18 | $1,395 | $525.36 | 37.7% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2020 | 13 | 40 | $14,440 | $5,320 | 36.8% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 56 | 80 | $14,640 | $5,243 | 35.8% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 91 | 161 | $11,270 | $4,719 | 41.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 29 | 48 | $12,720 | $4,689 | 36.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 40 | 74 | $6,142 | $3,901 | 63.5% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 21 | 21 | $8,337 | $3,077 | 36.9% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Facility | 2020 | 24 | 24 | $3,384 | $1,980 | 58.5% |
| 96367 | Infusion into a vein for therapy prevention or diagnosis additional sequential infusion up to 1 hour | Office | 2020 | 12 | 29 | $2,262 | $835.48 | 36.9% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Office | 2020 | 15 | 18 | $1,854 | $661.76 | 35.7% |
| 96375 | Injection of different drug or substance into a vein for therapy, diagnosis, or prevention | Office | 2020 | 11 | 34 | $2,822 | $518.11 | 18.4% |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | Office | 2020 | 13 | 34 | $68.00 | $18.85 | 27.7% |
About Dr. Warner Peng, MD
Dr. Warner Peng, MD is a Hematology & Oncology healthcare provider based in Oxnard, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/03/2008. The National Provider Identifier (NPI) number assigned to this provider is 1154584704.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Warner Peng, MD has received a total of $16,508 in payments from pharmaceutical and medical device companies, with $4,378 received in 2024. These payments were reported across 737 transactions from 68 companies. The most common payment nature is "Food and Beverage" ($16,304).
As a Medicare-enrolled provider, Peng has provided services to 672 Medicare beneficiaries, totaling 1,028 services with total Medicare billing of $66,425. Data is available for 4 years (2020–2023), covering 23 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Oxnard, CA
- Active Since 07/03/2008
- Last Updated 12/23/2021
- Taxonomy Code 207RH0003X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1154584704
Products in Payments
- KEYTRUDA (Biological) $958.46
- JAKAFI (Drug) $903.09
- REBLOZYL (Biological) $645.65
- KISQALI (Drug) $617.36
- Lenvima (Drug) $615.45
- XPOVIO (Drug) $424.08
- IMBRUVICA (Drug) $365.63
- MONJUVI (Drug) $353.98
- IBRANCE (Drug) $352.18
- OPDIVO (Biological) $351.01
- DARZALEX (Biological) $346.77
- CABOMETYX (Drug) $342.73
- ORGOVYX (Drug) $323.92
- Enhertu (Drug) $315.55
- ZEJULA (Drug) $292.09
- IMFINZI (Biological) $285.64
- MEKINIST (Drug) $264.53
- Cabometyx (Drug) $257.72
- LIBTAYO (Biological) $247.93
- ICLUSIG (Drug) $246.94
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Oxnard
Dr. Kevin Chang, Md, MD
Hematology & Oncology — Payments: $27,258
Hematology & Oncology $27,258
Dr. Kooros Parsa, Md, MD
Hematology & Oncology — Payments: $13,661
Hematology & Oncology $13,661
Fariborz Mortazavi, M.d, M.D
Hematology & Oncology — Payments: $13,276
Hematology & Oncology $13,276
Dr. Todd Yates, D.o, D.O
Hematology & Oncology — Payments: $8,148
Hematology & Oncology $8,148
Dr. Rosemary Mcintyre, Md, MD
Hematology & Oncology — Payments: $445.29
Hematology & Oncology $445.29